Enanta Pharmaceuticals, Inc. (ENTA)
Largest Insider Buys in Sector
ENTA Stock Price History Chart
ENTA Stock Performance
About Enanta Pharmaceuticals, Inc.
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic …
Insider Activity of Enanta Pharmaceuticals, Inc.
Over the last 12 months, insiders at Enanta Pharmaceuticals, Inc. have bought $0 and sold $407,330 worth of Enanta Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Enanta Pharmaceuticals, Inc. have bought $0 and sold $2.8M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1,000 shares for transaction amount of $24,445 was made by Gardiner Nathaniel S. (Sr. VP & General Counsel) on 2016‑05‑11.
List of Insider Buy and Sell Transactions, Enanta Pharmaceuticals, Inc.
| 2024-12-06 | Sale | President and CEO | 5,142 0.0244% | $8.06 | $41,445 | -21.13% | ||
| 2024-12-06 | Sale | Chief Scientific Officer | 2,591 0.0123% | $8.06 | $20,883 | -21.13% | ||
| 2024-12-06 | Sale | Chief Fin. & Admin Officer | 2,591 0.0123% | $8.06 | $20,883 | -21.13% | ||
| 2024-12-06 | Sale | Chief Business Officer | 2,283 0.0108% | $8.06 | $18,401 | -21.13% | ||
| 2024-12-06 | Sale | Chief Product Strategy Officer | 2,283 0.0108% | $8.06 | $18,401 | -21.13% | ||
| 2024-12-06 | Sale | Chief Medical Officer | 866 0.0041% | $8.06 | $6,980 | -21.13% | ||
| 2024-07-15 | Sale | Chief Medical Officer | 5,375 0.0355% | $17.08 | $91,805 | 0.00% | ||
| 2024-07-12 | Sale | Chief Medical Officer | 2,271 0.0132% | $15.04 | $34,156 | 0.00% | ||
| 2024-07-11 | Sale | Chief Medical Officer | 4,299 0.0251% | $15.07 | $64,786 | 0.00% | ||
| 2024-06-17 | Sale | Chief Product Strategy Officer | 7,266 0.0315% | $12.33 | $89,590 | -4.64% | ||
| 2023-12-13 | Sale | director | 15,295 0.0684% | $9.12 | $139,490 | +27.75% | ||
| 2023-12-05 | Sale | President and CEO | 7,230 0.0351% | $9.63 | $69,625 | +31.04% | ||
| 2023-12-05 | Sale | Sr. VP, R&D & CSO | 2,412 0.0117% | $9.63 | $23,228 | +31.04% | ||
| 2023-12-05 | Sale | Sr. VP, Finance & Admin. & CFO | 2,412 0.0117% | $9.63 | $23,228 | +31.04% | ||
| 2023-12-05 | Sale | Sr. VP & General Counsel | 2,412 0.0117% | $9.63 | $23,228 | +31.04% | ||
| 2023-12-05 | Sale | Sr. VP, New Prod. Strat. & Dev | 2,125 0.0103% | $9.63 | $20,464 | +31.04% | ||
| 2023-12-05 | Sale | Sr. VP, Business Dev. | 2,125 0.0103% | $9.63 | $20,464 | +31.04% | ||
| 2023-12-05 | Sale | Sr. VP & CMO | 534 0.0026% | $9.63 | $5,142 | +31.04% | ||
| 2023-03-15 | Sale | Sr. VP & CSO | 13,925 0.0661% | $44.45 | $618,960 | -67.56% | ||
| 2023-03-15 | Sale | Treasurer and CFO | 10,440 0.0495% | $44.43 | $463,802 | -67.56% |
Insider Historical Profitability
| SCHUHSLER HELMUT | 380487 1.7952% | $6.10 | 1 | 3 | +19.31% | |
| TVM V LIFE SCIENCE VENTURES GMBH & CO KG | 10 percent owner | 276999 1.307% | $6.10 | 1 | 7 | +19.31% |
| Gardiner Nathaniel S. | Sr. VP & General Counsel | 68154 0.3216% | $6.10 | 3 | 2 | +9.2% |
| SAINTS CAPITAL GRANITE, L.P. | 10 percent owner | 16904 0.0798% | $6.10 | 1 | 8 | +19.31% |
| Vance Terry | director | 5800 0.0274% | $6.10 | 2 | 1 | +8.96% |
Institutional Investor Ownership
| Farallon Capital | $36.58M | 9.89 | 2.1M | +3.46% | +$1.22M | 0.26 | |
| Morgan Stanley | $35.71M | 9.66 | 2.05M | +74.34% | +$15.23M | <0.01 | |
| The Vanguard Group | $33.66M | 9.1 | 1.93M | +7.49% | +$2.34M | <0.01 | |
| BlackRock | $32.11M | 8.68 | 1.84M | -4.94% | -$1.67M | <0.01 | |
| Armistice Capital Llc | $21.58M | 5.84 | 1.24M | -40.12% | -$14.46M | 0.07 |